magnesium sulfate; polyethylene glycol 3350; potassium chloride; sodium chloride; sodium sulfate · Azurity · NDA 215344
Suflave
Earliest generic entry, as listed
2 Aug 2044
Blocked by patent: US 12290529.
Listed patents · 4 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 12290529 | drug product · sets the listed date | 2 Aug 2044 |
| US 12239659 | use U-4143 | 14 Jun 2044 |
| US 12433914 | use U-4143 | 14 Jun 2044 |
| US 12594298 | drug product | 14 Jun 2044 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 215344 · 001 · RLD | for solution, oral | 0.9GM/BOT;178.7GM/BOT;1.12GM/BOT;0.5GM/BOT;7.3GM/BOT | 2 Aug 2044 |
Expired or delisted (1)
- NP · 15 Jun 2026